Can you be on Mounjaro for life — and what does the evidence say?

You've lost the weight, so why would stopping be a problem?

Imagine you're six months in. The number on the scale has moved significantly, your clothes fit differently, and a friend asks whether you'll just come off it now. It's a reasonable question. The honest answer is that for most people, stopping tirzepatide reverses a large part of what the medicine achieved.

SURMOUNT-4, an extension study of tirzepatide, showed that participants who switched to placebo after a period of active treatment regained a substantial proportion of their lost weight over the following year. The mechanism isn't complicated: tirzepatide works by acting on two gut-hormone receptors that regulate appetite and how full you feel. When you stop the medicine, those signals return to their previous pattern. The biology of tirzepatide hasn't permanently reprogrammed anything, it's managing an ongoing physiological tendency, not curing a discrete illness.

This is exactly why many obesity specialists now argue that weight management medicines should be thought of like antihypertensives. You wouldn't expect blood pressure to stay low after stopping the tablet; the same logic applies here. Whether that framing fits your personal situation is something to work through with your prescriber, and if you want a clinically grounded overview of whether you can take Mounjaro for life, that's a good place to start before deciding anything based on how the scale looks today.

What the UK licence and NICE guidance actually permit

The Mounjaro UK licence sets no upper time limit on treatment. Eli Lilly's authorisation covers adults with a qualifying BMI alongside a reduced-calorie diet and increased physical activity, with no mandatory stopping point built in. NICE's appraisal of tirzepatide (TA1026) does include one specific checkpoint: if a patient on the highest tolerated dose has not lost at least 5% of their body weight after six months, continuing the medicine should be reviewed. That review is a safeguard, not a routine exit point for people who are responding well.

It's also worth being clear about what NICE TA1026 does and doesn't cover. The appraisal describes NHS eligibility criteria and thresholds. Private prescribing (like the route through a GPhC-registered online pharmacy) follows the medicine's SmPC rather than NICE's specific NHS funding criteria. A private prescriber can lawfully continue treatment beyond the NHS thresholds if clinical benefit continues and the medicine remains suitable.

One practical note on timing: if you're planning a holiday or your prescription falls near a bank holiday, it's worth confirming your next order a few days early rather than relying on a tight turnaround. Continuity of supply matters more with a medicine you may be on for the long term, and our page covering whether you can stay on Mounjaro for life sets out what that ongoing commitment involves from a clinical and regulatory perspective.

What ongoing prescribing looks like in practice

Long-term use does not mean unsupervised use. Every repeat requires a prescriber to look again at your case, checking weight progress, any new health conditions, any medicines started since your last order, and whether the dose you're on is still appropriate. The NHS's guidance on tirzepatide reflects this: the medicine is reviewed throughout treatment, not signed off once and left to run.

At nume, a named clinician (a GPhC-registered Independent Prescriber, not automated software) reads every repeat consultation before it goes to our pharmacy. If something has changed, they act on it. You can read more about how our clinical team approaches this on the clinical team profile page. The short version: no prescription leaves our pharmacy without a real person making a considered decision.

It is also worth knowing that tirzepatide carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring as a relatively new medicine. That doesn't mean it's considered unsafe, it means the regulators are collecting longer-term data, which is standard practice for recently licensed treatments. Side effects or unexpected reactions should be reported via the MHRA Yellow Card scheme.

The cost side of long-term treatment

Being on Mounjaro indefinitely is a financial commitment as well as a clinical one. Eli Lilly increased UK list prices from September 2025, and private monthly costs now typically range from around £149 to £375 depending on dose and provider, figures that compound significantly over years rather than months. Our page on the UK Mounjaro price increase has the full context. For anyone thinking about long-term treatment, the BMJ's coverage of Mounjaro offers useful independent clinical perspective on what sustained use means in practice, and understanding that is a sensible part of the conversation with your prescriber. It's also one reason to understand exactly what a quoted price includes: consultation fees, prescription costs, aftercare access and delivery all vary between services, and those differences add up over time. See the treatment options page for how nume structures its pricing. The NHS route remains an option for eligible patients, though if you want a fuller picture of what staying on Mounjaro for life looks like, including the clinical, financial and practical considerations, that page brings it all together. Access through specialist services under Wegovy or through the phased Mounjaro rollout involves waiting lists that are not short for most people right now.